What is the recommended treatment for Guillain‑Barré syndrome?

Treatment of Guillain-Barré Syndrome

Treat GBS with intravenous immunoglobulin (IVIg) 0.4 g/kg daily for 5 consecutive days OR plasma exchange (200-250 ml/kg over 5 sessions) in patients unable to walk unaided within 2 weeks of weakness onset. 1, 2

First-Line Treatment Options

IVIg and plasma exchange are equally effective for GBS, but IVIg is typically preferred as first-line therapy because it is easier to administer, more widely available, and has comparable adverse event rates (though plasma exchange was more frequently discontinued in early studies) 1.

Specific Dosing:

• IVIg: 0.4 g/kg body weight daily for 5 consecutive days (total 2 g/kg)
• Plasma Exchange: 200-250 ml plasma/kg body weight divided over 5 sessions (12-15 L total over 1-2 weeks) 1, 2

Treatment Timing:

• Initiate treatment in patients unable to walk unaided within 2 weeks of weakness onset 2
• Plasma exchange can be considered up to 4 weeks after onset 2
• Treatment may still be considered 2-4 weeks after onset based on clinical judgment 2

What Does NOT Work

Do not use corticosteroids - eight randomized controlled trials showed no benefit, and oral corticosteroids actually had negative effects on outcome 1. The guideline weakly recommends against IV corticosteroids as well 2.

Do not combine plasma exchange followed by IVIg - this sequential approach is no more effective than either treatment alone 1.

Do not routinely give a second IVIg course to patients with poor prognosis - the guidelines recommend against this practice 2, though it remains common in clinical practice when patients show insufficient response.

Special Populations

Miller Fisher Syndrome (MFS)

Treatment is generally not recommended for pure MFS as most patients recover completely without treatment within 6 months. However, monitor closely as some develop limb weakness, bulbar/facial palsy, or respiratory failure 1.

Pregnant Women

Both IVIg and plasma exchange are safe, but IVIg is preferred due to fewer monitoring requirements 1.

Children

Use the same adult regimen: 0.4 g/kg daily for 5 days rather than the compressed 2-day regimen (2 g/kg over 2 days), as treatment-related fluctuations occurred more frequently with the shorter course (5/23 vs 0/23 children) 1.

Managing Insufficient Response

Approximately 40% of patients do not improve within 4 weeks of standard treatment 1. While repeating treatment or switching therapies is common practice, no evidence currently supports that this improves outcomes 1.

Treatment-Related Fluctuations (TRFs)

TRFs occur in 6-10% of patients - defined as progression within 2 months after initial improvement or stabilization 1. Repeating the full IVIg or plasma exchange course is common practice for TRFs, though evidence is lacking 1.

Critical Monitoring Requirements

Monitor respiratory function routinely - up to 22% of patients require mechanical ventilation within the first week, and respiratory insufficiency can occur without dyspnea symptoms 1.

ICU Admission Criteria:

• Evolving respiratory distress with imminent insufficiency
• Severe autonomic dysfunction (arrhythmias, blood pressure instability)
• Severe swallowing dysfunction or diminished cough reflex
• Rapid progression of weakness 1

Signs of Respiratory Distress:

• Breathlessness at rest or during talking
• Inability to count to 15 in single breath
• Use of accessory respiratory muscles
• Vital capacity <15-20 ml/kg or <1 L
• Abnormal arterial blood gas or pulse oximetry 1

Prognostic Tools

Use the Erasmus GBS Respiratory Insufficiency Score (EGRIS) to calculate probability (1-90%) of requiring ventilation within 1 week 1.

Use the modified Erasmus GBS Outcome Score (mEGOS) at admission to predict walking ability at 6 months 1, 2.

Common Pitfalls

• Do not wait for CSF or electrophysiology results to initiate treatment if clinical suspicion is high and patient cannot walk unaided
• Do not assume dyspnea will precede respiratory failure - measure vital capacity regularly
• Do not diagnose acute-onset CIDP prematurely - consider this diagnosis only if progression continues beyond 8 weeks or patient has ≥3 treatment-related fluctuations 1
• Do not overlook pain management - consider gabapentinoids, tricyclic antidepressants, or carbamazepine 2